Cingulate therapeutics llc
WebCingulate Inc. 1,061 followers. 2mo. Today we announce our Q3 2024 financial results and provided a clinical and business update, including updated study timelines for our lead … WebJan 1, 2024 · EX-10.10 2 ex10-10.htm . Exhibit 10.10 . AMENDMENT TO EMPLOYMENT AGREEMENT . This AMENDMENT is made and effective as of January 1, 2024 by and between CINGULATE THERAPEUTICS LLC, a Delaware Limited Liability Company, whose principal address is 1901 W. 47 th Place, 3 rd Floor, Kansas City, KS 66205 (the …
Cingulate therapeutics llc
Did you know?
WebShane J. Schaffer founded Cingulate, Inc., Cingulate Works, Inc. and Cingulate Therapeutics LLC. Presently, Dr. Schaffer holds the position of Chairman & Chief Executive Officer for Cingulate, Inc. and Chairman & Chief Executive Officer of Cingulate Therapeutics LLC and Chairman & Chief Executive Officer of Cingulate Works, Inc. … WebCingulate Therapeutics, Kansas City, Kansas. 92 likes · 2 were here. Cingulate Therapeutics, LLC (CTx) is a privately held, clinical stage bio-pharmaceutical company foc
WebAug 8, 2024 · Cingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit ... WebCingulate Therapeutics. Jan 2024 - Present4 years 4 months. Kansas City, Kansas.
WebExhibit 10.1 . AMENDMENT TO EMPLOYMENT AGREEMENT . This AMENDMENT is made and effective as of April 1, 2024 by and between CINGULATE THERAPEUTICS … WebMay 31, 2024 · Cingulate Therapeutics LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products …
WebSep 14, 2024 · Prior to the closing of this IPO, the company will affect a “reorganization merger” in which Cingulate Inc. will acquire Cingulate Therapeutics LLC (CTx) through the merger of a wholly-owned ...
WebSep 23, 2024 · EX-10.7 6 ex10-7.htm . Exhibit 10.7 . EMPLOYMENT AGREEMENT . This AGREEMENT (this “Agreement”) is made and effective as of this 23rd day of September, 2024 by and between CINGULATE THERAPEUTICS LLC, a Delaware Limited Liability Company, whose principal address is 1901 W. 47 th Place, 3 rd Floor, Kansas City, KS … incompatibility\u0027s 4yWebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third … 10 Mar 2024 Cingulate Inc. Reports Fourth Quarter and Full Year 2024 Financial … Pipeline Overview. Cingulate® completed a proof-of-concept trial in human subjects … Cingulate Inc. 1901 W 47th Place Kansas City, KS 66205 (913) 942-2300 … Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and … About Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage … Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member … incompatibility\u0027s 51WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ … incompatibility\u0027s 4zWebCingulate. Manufacturing · Kansas, United States · <25 Employees . Cingulate is a clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release drug … incompatibility\u0027s 5kincompatibility\u0027s 58WebDec 8, 2024 · Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to … incompatibility\u0027s 5gWebJan 9, 2024 · Cingulate Therapeutics LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing the Company's innovative, precision ... incompatibility\u0027s 5q